Irritable Bowel Syndrome Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Condition (Irritable Bowel Syndrome for Constipation, Irritable Bowel Syndrome for Diarrhea, Others), By Drugs (Alosetron, Rifaximin, Eluxadoline, Linaclotide, Lubiprostone, Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies) and Region Forecast 2019-2030

Irritable Bowel Syndrome Drugs Market Regional Analysis

North America irritable bowel syndrome market is projected to have the significant growth over the forecast period owing to the high prevalence rates of syndrome coupled with the well-established healthcare infrastructure and awareness in public related to syndrome. According to the Center for Disease Control and prevention (CDC), an estimated 3 million adults were diagnosed with irritable bowel syndrome in 2015.

Asia Pacific market expected to gain the lucrative opportunity for growth owing to the development in healthcare infrastructure and huge base of patient pool. Market players in Asia Pacific region are adopting the strategies such as collaboration, new product launches and expansion to strengthen its position.

For instance, in March 2017, Astellas Pharma Inc. has launched LINZESS tablets, a guanylate cyclase receptor agonist to treat irritable bowel syndrome with constipation into Japan market. Europe market anticipated to have the notable growth rate owing to presence of the major market players and active development of drugs to treat the irritable bowel syndrome.